Germline copy number variation of genes involved in chromatin remodelling in families suggestive of Li-Fraumeni syndrome with brain tumours

European Journal of Human Genetics

Volumn 21, Issue 12, 2013, Pages 1369-1376

  Aury Landas, Juliette ^a,b   Bougeard, Gaëlle ^a,b   Castel, Hélène ^b,c   Hernandez Vargas, Hector ^d   Drouet, Aurélie ^a,b   Latouche, Jean Baptiste ^a,b,e   Schouft, Marie Thérèse ^b,c   Férec, Claude ^f   Leroux, Dominique ^g   Lasset, Christine ^h   Coupier, Isabelle ⁱ   Caron, Olivier ^j   Herceg, Zdenko ^d   Frebourg, Thierry ^a,b,e   Flaman, Jean Michel ^a,b  

^a UNIVERSITÉ DE ROUEN   (France)

^b UNIVERSITY OF ROUEN   (France)

^c Université de Rouen   (France)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^e ROUEN UNIVERSITY HOSPITAL   (France)

^f INSERM   (France)

^g GRENOBLE UNIVERSITY HOSPITAL   (France)

^h Cancer Genetics   (France)

ⁱ CENTRE VAL D AURELLE   (France)

^j INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

chromatin remodelling; copy number variation; Li Fraumeni syndrome; SIRT3; TP53

Indexed keywords

ADOLESCENT; APOPTOSIS; ARTICLE; BRAIN TUMOR; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CHROMATIN; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA METHYLATION; FAMILIAL CANCER; FEMALE; GENE; GENE DUPLICATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; HUMAN CELL; KDM1A GENE; MAJOR CLINICAL STUDY; MALE; MTA3 GENE; PRIORITY JOURNAL; SIRT3 GENE; TP53 GENE; TRRAP GENE; TUMOR SUPPRESSOR GENE;

ACETYLATION; ADOLESCENT; APOPTOSIS; BRAIN NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CHROMATIN; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; FEMALE; GERM-LINE MUTATION; HUMANS; LI-FRAUMENI SYNDROME; MALE; SIRTUIN 3; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84887625811     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2013.68     Document Type: Article

References (45)

1. Li FP, Fraumeni Jr JF: Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 1969; 43: 1365-1373.
2. Li FP, Fraumeni JF: Soft-tissue sarcomas, breast cancer, and other neoplasms a familial syndrome? Ann Intern Med 1969; 71: 747-752.
3. Li FP, Fraumeni JF, Mulvihill JJ et al: A cancer family syndrome in twenty-four kindreds. Cancer Res 1988; 48: 5358-5362.
4. Malkin D: Li-Fraumeni syndrome. Genes Cancer 2011; 2: 475-484.
5. Chompret A, Abel A, Stoppa-Lyonnet D et al: Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 2001; 38: 43-47.
6. BougeardG, Sesboüé R, Baert-Desurmont S et al: Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 2008; 45: 535-538.
7. Tinat J, Bougeard G, Baert-Desurmont S et al: 2009; Version of the Chompret Criteria for Li Fraumeni syndrome. J Clin Oncol 2009; 27: e108-e109.
8. Ruijs MWG, Verhoef S, Rookus MA et al: TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 2010; 47: 421-428.
9. Scherer SW, Lee C, Birney E et al: Challenges and standards in integrating surveys of structural variation. Nat Genet 2007; 39: S7-15.
10. Conrad DF, Pinto D, Redon R et al: Origins and functional impact of copy number variation in the human genome. Nature 2010; 464: 704-712.
11. Zhang F, Gu W, Hurles ME, Lupski JR: Copy number variation in human health, disease, and evolution. Annu Rev Genomics Hum Genet 2009; 10: 451-481.
12. Stankiewicz P, Lupski JR: Structural variation in the human genome and its role in disease. Annu Rev Med 2010; 61: 437-455.
13. Krepischi ACV, Pearson PL, Rosenberg C: Germline copy number variations and cancer predisposition. Future Oncol 2012; 8: 441-450.
14. Lee C, Iafrate AJ, Brothman AR: Copy number variations and clinical cytogenetic diagnosis of constitutional disorders. Nat Genet 2007; 39: S48-S54.
15. Iafrate AJ, Feuk L, Rivera MN et al: Detection of large-scale variation in the human genome. Nat Genet 2004; 36: 949-951.
16. Bougeard G, Brugières L, Chompret A et al: Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene. Oncogene 2003; 22: 840-846.
17. Charbonnier F, Raux G, Wang Q et al: Detection of exon deletions and duplications of the mismatch repair genes in hereditary nonpolyposis colorectal cancer families using multiplex polymerase chain reaction of short fluorescent fragments. Cancer Res 2000; 60: 2760-2763.
18. Vezain M, Saugier-Veber P, Goina E et al: A rare SMN2 variant in a previously unrecognized composite splicing regulatory element induces exon 7 inclusion and reduces the clinical severity of spinal muscular atrophy. Hum Mutat 2010; 31: E1110-E1125.
19. Perzelová A, Máciková I, Mráz P, Bízik I, Steno J: Characterization of two new permanent glioma cell lines 8-MG-BA and 42-MG-BA. Neoplasma 1998; 45: 25-29.
20. Ory DS, Neugeboren BA, Mulligan RC: A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci USA 1996; 93: 11400-11406.
21. Latouche JB, Sadelain M: Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol 2000; 18: 405-409.
22. Hernandez-Vargas H, Lambert M-P, Le Calvez-Kelm F et al: Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS ONE 2010; 5: e9749.
23. Braun CJ, Zhang X, Savelyeva I et al: p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 2008; 68: 10094-10104.
24. Huang DW, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
25. Huang DW, Sherman BT, Lempicki RA: Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37: 1-13.
26. Alhazzazi TY, Kamarajan P, Verdin E, Kapila YL: SIRT3 and cancer: tumor promoter or suppressor? Biochim Biophys Acta 2011; 1816: 80-88.
27. Scher MB, Vaquero A, Reinberg D: SirT3 is a nuclear NAD+-dependent histone deacetylase that translocates to the mitochondria upon cellular stress. Genes Dev 2007; 21: 920-928.
28. Noushmehr H, Weisenberger DJ, Diefes K et al: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17: 510-522.
29. Wang Y, Zhang H, Chen Y et al: LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 2009; 138: 660-672.
30. Huang J, Sengupta R, Espejo AB et al: p53 is regulated by the lysine demethylase LSD1. Nature 2007; 449: 105-108.
31. Moissiard G, Cokus SJ, Cary J et al: MORC family ATPases required for heterochromatin condensation and gene silencing. Science 2012; 336: 1448-1451.
32. Fujita N, Jaye DL, Kajita M et al: MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 2003; 113: 207-219.
33. Luo J, Su F, Chen D, Shiloh A, Gu W: Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000; 408: 377-381.
34. Ard PG, Chatterjee C, Kunjibettu S, Adside LR, Gralinski LE, McMahon SB: Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP acetyltransferase complexes. Mol Cell Biol 2002; 22: 5650-5661.
35. Wurdak H, Zhu S, Romero A et al: An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation. Cell Stem Cell 2010; 6: 37-47.
36. Wei X, Walia V, Lin JC et al: Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 2011; 43: 442-446.
37. Haigis MC, Deng C-X, Finley LWS, Kim H-S, Gius D: SIRT3 is a mitochondrial tumor suppressor: a scientific tale that connects aberrant cellular ROS, the Warburg effect, and carcinogenesis. Cancer Res 2012; 72: 2468-2472.
38. He W, Newman JC, Wang MZ, Ho L, Verdin E: Mitochondrial sirtuins: regulators of protein acylation and metabolism. Trends Endocrinol Metab 2012; 23: 467-476.
39. Iwahara T, Bonasio R, Narendra V, Reinberg D: SIRT3 functions in the nucleus in the control of stress-related gene expression. Mol Cell Biol 2012; 32: 5022-5034.
40. Finley LWS, Carracedo A, Lee J et al: SIRT3 opposes reprogramming of cancer cell metabolism through HIF1a destabilization. Cancer Cell 2011; 19: 416-428.
41. Ashraf N, Zino S, Macintyre A et al: Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer 2006; 95: 1056-1061.
42. Li S, Banck M, Mujtaba S, Zhou M-M, Sugrue MM, Walsh MJ: p53-induced growth arrest is regulated by the mitochondrial SirT3 deacetylase. PLoS One 2010; 5: e10486.
43. Schwartzentruber J, Korshunov A, Liu X-Y et al: Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012; 482: 226-231.
44. Yan H, Parsons DW, Jin G et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-773.
45. Turcan S, Rohle D, Goenka A et al: IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012; 483: 479-483.